The radiopharmaceutical, I-131-MIP-1466, which is designed to deliver a therapeutic dose of radiation to metastatic prostate cancer, will enter a clinical trial to evaluate its efficacy and benefits for patients.
The team at Johns Hopkins In-Vivo Cellular and Molecular Imaging Center in Baltimore is using novel imaging tools to discover new early detection methods for cancers existing in cells, and study its prevention and elimination before spreading to other organs and tissues.
The results of three studies, released Oct. 21 during a meeting of the North Central Section of the American Urological Association, validated previous research that suggested C-11 choline PET/CT scans can be utilized as a staging and potentially therapeutic tool in prostate cancer.
89Zr-desferrioxamine B-7E11 displays high tumor-to-background tissue contrast in immuno-PET and can be used as a tool to monitor and quantify with high specificity tumor response in prostate-specific membrane antigen (PSMA)-positive prostate cancer, according to research published in the October issue of the Journal of Nuclear Medicine.
MD Anderson Cancer Center in Houston has initiated orders of Cesium-131 brachytherapy seeds from IsoRay, as it continues its clinical research study investigating brachytherapy's ability to help control intermediate risk prostate cancer, which is a classification of early stage prostate cancer that has shown a tendency to recur following standard treatment.
Over the next decade, the population of cancer survivors over 65 years of age will increase by approximately 42 percent, according to a report published in the October issue of Cancer Epidemiology, Biomarkers & Prevention.
Researchers at UCLA’s Jonsson Comprehensive Cancer Center have developed a gene-based imaging system to target castration resistant prostate cancers (CRPCs), potentially allowing oncologists to find and treat metastases faster.
The synthetic amino acid analog radiotracer anti-1-amino-3- 18F-fluorocyclobutane-1-carboxylic acid ( anti-3- 18F-FACBC) with PET/CT is more sensitive than 111In-capromab pendetide in the detection of recurrent prostate carcinoma.
A steady reduction in overall cancer death rates translates into the avoidance of about 898,000 deaths from cancer between 1990 and 2007, according to the latest statistics from the American Cancer Society (ACS).
A class of engineered nanoparticles—Raman-silica-gold-nanoparticles—has been shown to be safe when administered by two alternative routes in mouse models, according to a study published April 20 in Science Translational Medicine. This marks the first step up the ladder of toxicology studies that, within a year and a half, could yield to human trials of these agents for detection of colorectal and possibly other cancers.
Theragenics has signed a non-exclusive agreement with Oncura to distribute its brachytherapy-related products in North America.
Overall cancer incidence in the U.S. decreased by nearly 1 percent per year between 2003 and 2007, with mortality falling by twice that figure across all four years, thanks largely to advances in diagnostic imaging, showed the findings of a report published in the April edition of the Journal of the National Cancer Institute.
Seven new research projects on regenerative medicine and nanomedicine received $16 million in funding. The studies were co-funded by the Canadian Institutes of Health Research and the Canadian Space Agency.
IsoRay, which manufactures Cesium-131 used in internal radiation therapy (brachytherapy) for the treatment of lung, brain, colon, head and neck, ocular melanoma and prostate cancer, has announced its second quarter financial results that showed narrowing of net losses despite a decrease in net sales, which ended Dec. 31, 2010.
E.U. mortality rates from cancer are expected to maintain their nearly universal descent in 2011, with overall rates projected to fall by 7 percent, despite a 25-million person increase in the absolute number of deaths at 1.28 million, according to a study published Feb. 8 in the Annals of Oncology.
|
RSS 
